Medicsight Announces Chinese State Food and Drug Administration Approval for MedicRead...

Medicsight Announces Chinese State Food and Drug Administration Approval for
MedicRead Colon Workstation

NEW YORK, April 10 /PRNewswire-FirstCall/ -- Medicsight PLC, a subsidiary
of MGT Capital Investments, Inc. (AMEX: MGT), and an industry leader in the
development of Computer-Aided Detection (CAD) and image analysis software
which assists in the early detection and diagnosis of disease, today announced
that it has received approval from the Chinese State Food and Drug
Administration ("SFDA") for its MedicRead Colon workstation. Medicsight will
launch this workstation via a Chinese dealer network which gives the Company
access to almost 1000 sales representatives.
David Sumner, Chief Executive of Medicsight, commented: "This is another
significant milestone for Medicsight and we are delighted to have received
approval from the SFDA. China is one of the world's fastest growing medical
imaging markets and is one of Medicsight's core target markets, with a high
installed base of MDCT (Multidetector Computed Tomography), high incidence of
colorectal cancer and a large population. In anticipation of this approval,
Medicsight has been working closely with its Chinese dealer network in
preparation for the national launch in Guangzhou during the May Chinese
Society of Abdominal Radiology congress."
President Qi Ji, President of the Chinese Society of Radiology, said, "We
have been working with Medicsight for three years as part of their Chinese
clinical program. We have been delighted with the performance of Medicsight's
products, which have proven to make a marked difference in the speed and
accuracy of our diagnosis. As the number of patients in China increases, CAD
software is becoming increasingly important for radiologists where improved
workflow and productivity support their efforts to save lives. I am delighted
that Medicsight's products will now be available to radiologists across
China."
MedicRead Colon is an advanced visualization workstation for CT
Colonography and combines Medicsight's ColonCAD computer-aided detection
technology with 3D imaging tools to assist radiologists in the detection of
colorectal neoplasia (polyps). This software reduces the workload of
radiologists by automatically highlighting suspicious areas on scan images,
and may also help radiologists detect possibly malignant tumors at an early
stage when treatment is most likely to be successful.
About MGT Capital Investments, Inc.
MGT Capital Investments, Inc. is a holding company that focuses on
investments in the global healthcare information technology market. The
Company has two subsidiaries, Medicsight PLC and Medicexchange PLC.
Medicsight PLC (AIM: MDST) is a leading developer of computer-aided
detection (CAD) software solutions. Medicsight's CAD solutions help
clinicians utilizing Computed Tomography (CT) scans to identify, measure and
analyze suspicious pathology within the colon and lungs. The Medicsight CAD
products are validated against one of the world's largest databases of
verified CT scan data collected from leading healthcare institutions from
around the world. Medicsight products allow radiologists and physicians to
review scans more quickly and accurately -- saving both time and lives.
Medicexchange PLC provides medical imaging professionals with a global web
portal containing an online sales, jobs and information channel for
diagnostic, treatment and surgery planning solutions. This combined with a
variety of relevant clinical papers, training materials and content gives
these professionals access to information and products that they otherwise
would have difficulty accessing.
Additional information can be found at www.mgtci.com.
All forward-looking statements are made pursuant to the 'safe harbor'
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements are based on current management expectations that
involve risks and uncertainties that may result in such expectations not being
realized. Potential risks and uncertainties include, but are not limited to,
the risks described in company filings with the Securities and Exchange
Commission.
SOURCE MGT Capital Investments, Inc.

Investor & Media enquiries, Todd Fromer, +1-212-896-1215, tfromer@kcsa.com, or
Garth Russell, +1-212-896-1250, grussell@kcsa.com, both of KCSA Strategic
Communications for MGT Capital Investments, Inc.